September 15th
September 15th | September 16th | September 17th
9:00am-9:10am
Opening
9:10am-9:40am
John Moloney Memorial Lecture
Chair: Mitsuaki Yoshida, Cancer Institute of JFCR, Japan
Contributions of comparative studies of leukemia to advances in cancer research
9:40am-10:40am
Symposium1 Animal Models and Basic Research
Chairs: Keiya Ozawa, Jichi Medical University, Japan
Jacques Ghysdael, Institut Curie, France
Marrow failure, telomere attrition, and cancer
Dissection of pro-oncogenic pathways in mouse models of lymphoid leukemia
Non-myelinating Schwann cells in the bone marrow niche maintain hematopoietic stem cell hibernation through TGF-beta signaling
10:40am-11:00am
Coffee Break
11:00am-12:40pm
Symposium1 Animal Models and Basic Research
Chairs:
Toshio Kitamura, The Institute of medical Science, The University of Tokyo, Japan
Riccardo Dalla-Favera, Columbia University, USA
Challenges to Leukemia Animal Models in the Era of Next Generation Sequencing
Human adipose tissue_derived mesenchymal stem cell mediated cytosine deaminase/5-fluorocytosine prodrug therapy in intracranial glioblastoma C6 rat model
The Philadelphia Translocation: From Molecular Characterization to Mouse Models
Whole exome sequencing reveals a novel gene pathway deregulated in myeloid dysplasias
Two types of C/EBPa mutations collaborate in inducing leukemia in a mouse BMT model.
12:40pm-2:00pm
Lunch & Poster display
2:00pm-3:20pm
Symposium 2 MDS
Chairs:
Michael Lübbert, University of Freiburg, Medical Center, Germany
Yasushi Miyazaki, Nagasaki University Graduate School of Biomedical Sciences, Japan
Epigenetic approaches in MDS/AML treatment
LNK and other aspects of MPD
MDS among Atomic Bomb survivors
Paroxysmal Nocturnal Hemoglobinuria in Bone Marrow Failure
3:20pm-3:40pm
3:40pm-5:20pm
Symposium 3 MPD/CML
Chairs:
Andreas Hochhaus, Universitätsklinikum Jena, Germany
Arinobu Tojo, The University of Tokyo, Japan
Regulation of PRMTs in myeloid disorders
Clinical Significance of Additional Chromosomal Abnormalities in Ph-Positive and Ph-Negative Cells in Patients with Cronic Myeloid Leukemia Treated by Tyrosine Kinase Inhibitors
Mutations in the BCR-ABL kinase and the second generation TKI
The use of smo inhibitors or pegylated form of interferon for targeting chronic myeloid stem cells
Prognostic factors in CML
5:30pm-6:30pm
Welcome Reception
September 16th
September 15th | September 16th | September 17th
9:00am-9:20am
Opening of Jubilee Lectures
9:20am-10:00am
Special Lecture 1
Chair: Toshiki Watanabe, The University of Tokyo, Japan
Approaching a Successful HIV Preventive Vaccine
10:00am-10:40am
Special Lecture 2
Chair: Koichi Akashi, Kyushu University, Japan
Hematopoietic Stem Cells in the Hypoxic Niches
10:40am-11:00am
11:00am-11:40am
Special Lecture 3
Chair: Seishi Ogawa, Cancer Genomics Project, University of Tokyo, Japan
Oncogenomics of B cell lymphoma
11:40am-noon
Travel Award and Group Photo
noon-1:00pm
Lunch & Poster
1:00pm-1:40pm
Special Lecture 4
Chair: Hervé Dombret, University Paris 7 / Saint-Louis Hospital, France
Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia
1:40pm-2:20pm
Special Lecture 5
Chair: François Guilhot, CIC Inserm 0802, France
Approaching a cure in chronic myeloid leukemia
2:20pm-2:40pm
2:40pm-4:00pm
Symposium 4 AML1
Chairs:
David Grimwade, King's College London School of Medicine, United Kingdom
Tomoki Naoe, Nagoya University Graduate School of Medicine, Japan
Dendritic cell vaccination as a treatment to prevent relapse in acute myeloid leukemia
Developmental biology of leukemia stem cells
MicroRNAs in AML: prognostic and therapeutic relevance
Molecular mechanisms in therapy-related leukaemias
4:00pm-4:20pm
Coffee Break
4:20pm-5:40pm
Symposium 5 AML2
Chairs:
Yuzuru Kanakura, Osaka University Graduate School of Medicine, Japan
Clara D. Bloomfield, The Ohio State University , USA
Targeting the recepter Tyrosinc kinase-STAT axis in acute myeloid leukemia
Curability of older AML
Pathogenetic significance of deregulated transcription factors in acute leukemia
Several novel mutations increase the molecular heterogeneity in AML: Impact on the prognostic assessment
September 17th
September 15th | September 16th | September 17th
9:00am-9:20am
Yohei Ito Memorial Lecture
Chair: Rüdiger Hehlmann, Universität Heidelberg, Germany
Cell fusion and retrovirus rescue from non permissive cells-background and present molecular analysis
9:20am-11:00am
Symposium 6 Lymphoid leukemias:ALL/CLL
Chairs:
Dieter Hoelzer, Onkologikum, Frankfurt am Museumsufer, Germany
Claudia D Baldus, Charité, Campus Benjamin Franklin, Germany
Childhood Acute Lymphoblastic Leukemia: where are we?
Current Strategies and Future Options in Adult ALL
Biology and clinical significance of molecular alterations in adult ALL
Approaches to overcome environmentally-mediated drug resistance in ALL
Leukemic presentation of lymphoid malignancy with special reference to NK-cell neoplasms.
11:00am-11:20am
Coffee Break
11:20am-12:40pm
Symposium 7 Lymphomas and Myeloma
Chairs:
Masahiro Kizaki, Saitama Medical Center, Saitama Medical University, Japan
Anas Younes, MD Anderson, USA
New therapeutic approach for multiple myeloma: Development of novel molecular targeting agents
Discovering novel targets for mantle cell lymphoma
New treatments in Hodgkin disease
Treatment of T/NK-cell lymphoma: Japanese perspective
12:40pm-1:40pm
Lunch & Poster
International Symposium: Progress in HTLV-1 Research
1:40pm-3:20pm
Symposium8 HTLV-1 (1)
Chairs:
David Brighty, The University of Dundee , Scotland
Jun-ichi Fujisawa, Kansai Medecal University, Japan
Novel antiretroviral therapies for BLV and HTLV
HTLV-1 and HTLV-2 viruses similarities and major differences
Viral biofilms: a new infectious entity and a new mode of transmission for HTLV-1
Genetic deterrents for HTLV-1 persistence
Complex strategies of HTLV-1 expression and control of host cell turnover
3:20pm-3:40pm
Coffee Break
3:40pm-5:00pm
Symposium9 HTLV-1 (2)
Chairs:
Masao Seto, Aichi Cancer Center Research Institute, Japan
William Hall, University College Dublin, Ireland
Quantification of HTLV-1 clonality in leukaemia and non-malignant infection
Targeted Therapy for HTLV-1-Associated Myelopathy / Tropical Spastic Paraparesis
Molecular mechanisms of pathogenesis by HTLV-1
Attempt of new treatment in Adult T-cell Leukemia/Lymphoma (ATLL) mouse model
5:00pm-5:20pm
Coffee Break
5:20pm-6:40pm
Symposium 10 HTLV-1 / ATL
Chairs:
Kunihiro Tsukasaki, Nagasaki University, Japan
Renaud Mahieux, Ecole Normale Supérieure de Lyon, France
Frequenct clonal evolution takes palace in ATL patients
Recent advances in allogeneic hematopoietic stem cell transplantation for ATL
Can we cure adult T cell leukemia?
Development of the CCR4-targeted mAb therapy for Adult-T-cell leukemia/lymphoma (ATL)
6:40pm-6:50pm
Closing
